{"gene":"CTSS","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1992,"finding":"Human cathepsin S (CTSS) was cloned from alveolar macrophage cDNA and shown to encode a 28-kDa cysteine protease with elastinolytic activity, retaining ~25% of its pH 5.5 elastinolytic activity at pH 7.0, indicating broad pH range activity unlike other cathepsins.","method":"cDNA cloning, COS cell expression, active-site labeling with iodinated E-64 analogue, in vitro elastin degradation assay, Northern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted recombinant enzyme activity, active-site labeling, founding paper replicated by subsequent studies","pmids":["1373132"],"is_preprint":false},{"year":1994,"finding":"The human CTSS gene was mapped to chromosome 1q21 by fluorescence in situ hybridization; the gene structure resembles cathepsin L through exons 1–5 but has larger introns; 5'-flanking region contains AP1 sites and CA microsatellites but no TATA or CAAT box; tissue distribution is restricted (highest in spleen, heart, lung) with immunostaining detecting CTSS only in lung macrophages.","method":"Genomic library screening, FISH, Northern blotting, immunostaining","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — direct genomic mapping and tissue localization with multiple orthogonal methods","pmids":["8157683"],"is_preprint":false},{"year":1995,"finding":"Cystatin C inhibits cathepsin S with a Ki ~10⁻⁸ M even when the key N-terminal Leu-9 side chain (which contributes 200-fold to cathepsin B affinity and 50-fold to cathepsin L affinity) is absent, demonstrating that the structural determinants for cystatin C selectivity differ between cathepsin S and other cathepsins.","method":"Site-directed mutagenesis of cystatin C variants, kinetic inhibition assays against cathepsins B, H, L, S","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted inhibition with mutagenesis, rigorous kinetic analysis","pmids":["7890620"],"is_preprint":false},{"year":1996,"finding":"Cathepsin S is essential for complete proteolysis of the MHC class II-associated invariant chain (Ii) in B lymphoblastoid cells; specific CTSS inhibition caused accumulation of a 13 kDa Ii fragment, reduced SDS-stable class II complexes, and prevented peptide loading. Purified cathepsin S (but not cathepsins B, H, or D) specifically digested Ii from αβIi trimers in vitro to generate αβ-CLIP complexes capable of binding exogenous peptide.","method":"Specific small-molecule inhibition in B cells, in vitro reconstitution with purified cathepsins, Western blot, peptide-binding assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified enzyme + cell-based inhibitor studies, foundational paper with high citation count","pmids":["8612130"],"is_preprint":false},{"year":1998,"finding":"SCCA1 (serpin squamous cell carcinoma antigen 1) is a potent cross-class inhibitor of cathepsin S, forming stable complexes (t½ > 1155 min) via cleavage between Gly and Ser in its reactive-site loop, analogous to serpin–serine protease interactions; interaction with cathepsin S is 1:1 stoichiometry with second-order rate constants ≥1×10⁵ M⁻¹s⁻¹.","method":"Kinetic inhibition assays, SDS-PAGE complex detection, reactive-site loop cleavage mapping","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous kinetic analysis with purified proteins, multiple methods","pmids":["9548757"],"is_preprint":false},{"year":1998,"finding":"In J774 macrophages, the bulk of cellular cathepsin S is concentrated in late endosomes (as opposed to cathepsin H enriched in early endosomes), and cathepsin S is present in phagosomal fractions, establishing its trafficking itinerary within the endolysosomal system.","method":"Subcellular fractionation, enrichment of early endosomes/late endosomes/lysosomes/phagosomes, enzyme activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct subcellular fractionation with functional activity readout, rigorous organelle enrichment","pmids":["9545324"],"is_preprint":false},{"year":2001,"finding":"Cathepsin S (along with B and L) cleaves and inactivates secretory leucoprotease inhibitor (SLPI) between Thr67 and Tyr68, eliminating SLPI's active site and its anti-neutrophil elastase capacity; cathepsins L and S inactivated a 400-fold excess of SLPI within 15 min in catalytic fashion.","method":"In vitro cleavage assay with purified cathepsins, sequencing of cleavage site, anti-elastase activity assay, analysis of emphysema epithelial lining fluid","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with cleavage site identified, confirmed in patient samples","pmids":["11435427"],"is_preprint":false},{"year":2002,"finding":"Cathepsin S expressed in embryonic fibroblasts mediates invariant chain degradation and alters the peptide repertoire presented by MHC class II molecules; for a subset of antigens, cathepsin S is required for epitope generation, as shown by T cell hybridoma assays and mass spectrometric analysis of eluted peptides.","method":"Reconstituted fibroblast cell lines expressing cathepsin L or S, T cell hybridoma assays, mass spectrometry of MHC II-eluted peptides","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — reconstituted system with multiple readouts including mass spectrometry and functional T cell assay","pmids":["11884425"],"is_preprint":false},{"year":2006,"finding":"Cathepsin S promotes human preadipocyte differentiation at least in part by degrading fibronectin in the extracellular matrix; CTSS activity was highest in preadipocyte culture medium and decreased during differentiation; exogenous recombinant CTSS increased adipogenesis and markedly reduced the fibronectin network, while specific CTSS inhibition reduced lipid content and adipocyte marker expression 2-fold.","method":"Primary human preadipocyte cultures, recombinant CTSS treatment, specific inhibitor treatment, fibronectin immunostaining, adipocyte marker expression","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function with recombinant protein and inhibitor, multiple readouts, replicated in tissue sections","pmids":["16825321"],"is_preprint":false},{"year":2011,"finding":"Proteomic identification of cathepsin S cleavage sites (PICS) at pH 6.0 and 7.5 revealed that its specificity is primarily guided by aliphatic residues in P2, with limited importance of prime-site residues; the specificity profiles at both pH values were highly similar, consistent with broad pH activity.","method":"PICS (proteomic identification of protease cleavage sites) with mass spectrometry at pH 6.0 and 7.5","journal":"Journal of proteome research","confidence":"High","confidence_rationale":"Tier 1 — comprehensive substrate profiling by mass spectrometry at two pH conditions","pmids":["21967108"],"is_preprint":false},{"year":2014,"finding":"Cathepsin S specifically mediates breast-to-brain metastasis by proteolytic processing of the junctional adhesion molecule JAM-B, enabling blood-brain barrier transmigration; both macrophage- and tumor cell-derived CTSS contribute, and only combined depletion significantly reduced brain metastasis in vivo; pharmacological inhibition of CTSS significantly reduced experimental brain metastasis.","method":"Xenograft metastasis models (xenograft), CTSS depletion from tumor cells and macrophages separately and combined, in vitro BBB transmigration assay, proteolytic substrate identification (JAM-B cleavage), pharmacological inhibition in vivo","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — substrate identification (JAM-B cleavage) with in vivo validation, epistasis via combined depletion, pharmacological confirmation","pmids":["25086747"],"is_preprint":false},{"year":2014,"finding":"CD47-positive hepatocellular carcinoma (HCC) tumor-initiating cells preferentially secrete cathepsin S, which regulates liver tumor-initiating cell properties through a CTSS/protease-activated receptor 2 (PAR2) signaling loop; knockdown of CD47 suppressed this CTSS/PAR2 axis and reduced HCC growth in vivo.","method":"CD47 knockdown (morpholino), CTSS secretion measurement, PAR2 signaling assays, in vivo HCC tumor models","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function linking CD47/CTSS/PAR2 pathway with in vivo validation","pmids":["24523067"],"is_preprint":false},{"year":2014,"finding":"Cathepsin S cleaves PAR2 at E56↓T57 (distinct from the canonical trypsin site R36↓S37), acting as a biased agonist: it stimulates PAR2 coupling to Gαs/cAMP but does not mobilize intracellular Ca²⁺, activate ERK1/2, recruit β-arrestins, or induce PAR2 endocytosis. Cat-S causes PAR2- and TRPV4-dependent inflammation and hyperalgesia via adenylyl cyclase/PKA mechanisms in mouse dorsal root ganglia and in vivo.","method":"In vitro cleavage site mapping, HEK/KNRK cell signaling assays (cAMP, Ca²⁺, ERK, β-arrestin), Xenopus oocyte electrophysiology, mouse DRG nociceptor recordings, PAR2/TRPV4 knockout mice, intraplantar injection model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — cleavage site identified biochemically, biased signaling demonstrated with multiple orthogonal assays, confirmed in KO mice in vivo","pmids":["25118282"],"is_preprint":false},{"year":2014,"finding":"Cathepsin S is required for autophagic flux (including autophagosome-lysosome fusion) in tumor-associated macrophages (TAMs); CTSS knockout inhibited M2 macrophage polarization during tumor development and reduced tumor growth and metastasis; Cat S promotes M2 polarization through activation of autophagy.","method":"Cat S knockout mice, subcutaneous and hepatic metastasis tumor models, mCherry-GFP-LC3 autophagy flux assay, DQ-BSA degradation, TEM, flow cytometry for macrophage phenotype","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple in vivo and in vitro mechanistic readouts including autophagy flux assays","pmids":["24580730"],"is_preprint":false},{"year":2014,"finding":"Inhibition of cathepsin S in glioblastoma cells induces autophagy and mitochondrial apoptosis via ROS-mediated suppression of the PI3K/AKT/mTOR/p70S6K pathway and activation of JNK signaling; blocking autophagy attenuated cathepsin S inhibition-induced apoptosis, placing autophagy upstream of apoptosis in this pathway.","method":"Small-molecule CTSS inhibition, siRNA knockdown, ROS measurement, Western blot for PI3K/AKT/mTOR/JNK pathway components, autophagy inhibitors, cell death assays","journal":"Toxicology letters","confidence":"Medium","confidence_rationale":"Tier 2–3 — pharmacological and siRNA approaches with pathway epistasis, single lab","pmids":["24875536"],"is_preprint":false},{"year":2016,"finding":"CTSS mRNA is highly edited at its 3' UTR by ADAR1 via adenosine-to-inosine (A-to-I) RNA editing within AluJo/AluSx+ inverted repeat elements that form a long stem-loop; editing enables recruitment of the stabilizing RNA-binding protein HuR to the CTSS 3' UTR, controlling CTSS mRNA stability and expression. Hypoxia and inflammatory cytokines (IFN-γ, TNF-α) induce CTSS RNA editing and increase cathepsin S expression in endothelial cells.","method":"A-to-I editing sequencing, ADAR1 overexpression, RIP (RNA immunoprecipitation) of HuR, mRNA stability assays, patient atherosclerosis samples, cytokine treatment","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic epitranscriptomic regulation established with multiple orthogonal methods, validated in patient samples","pmids":["27595325"],"is_preprint":false},{"year":2017,"finding":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ in keratinocytes; CTSS cleaves pro-IL-36γ to generate the bioactive form IL-36γ-Ser18; this product induces psoriasiform changes in human skin-equivalent models; CTSS activity is strongly upregulated in psoriasis patient samples.","method":"Keratinocyte activity assay, small-molecule inhibitors, siRNA gene silencing, mass spectrometry cleavage-site identification, human skin-equivalent models, patient psoriasis samples","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — substrate cleavage site mapped biochemically, siRNA confirmation, functional skin model, patient validation","pmids":["28289191"],"is_preprint":false},{"year":2020,"finding":"Nicotine activates autophagy in vascular smooth muscle cells by inhibiting mTORC1 activity, promoting nuclear translocation of TFEB, which directly binds the CTSS promoter (demonstrated by ChIP-qPCR, EMSA, and luciferase reporter assay) to upregulate CTSS expression. mTORC1 inhibition promotes lysosomal exocytosis and CTSS secretion via a mechanism involving Rab10; CTSS upregulation promotes vascular smooth muscle cell migration and atherosclerosis in vivo.","method":"Western blot, immunofluorescent staining, ChIP-qPCR, EMSA, luciferase reporter assay, IP-MS (Rab10 interaction), live cell imaging, in vivo atherosclerosis model with CTSS inhibition","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1–2 — direct TFEB-CTSS promoter binding proven by three orthogonal methods, Rab10-mTORC1 interaction by IP-MS, in vivo confirmation","pmids":["32640907"],"is_preprint":false},{"year":2022,"finding":"CTSS directly disrupts epithelial barrier integrity in corneal epithelial cells; TNF-α and hyperosmolarity induce CTSS expression, while IL-37 suppresses TNF-α and CTSS expression and restores tight junction (ZO-1, occludin, claudin-1) and adherens junction (E-cadherin) protein integrity under hyperosmotic stress.","method":"Primary human corneal epithelial cell culture, hyperosmolar stress model, RT-qPCR, ELISA, immunofluorescent confocal microscopy, rhIL-37 and rhTNF-α treatment","journal":"The ocular surface","confidence":"Medium","confidence_rationale":"Tier 3 — cell-based model with direct barrier protein readout, mechanistic pathway defined, single lab","pmids":["36208723"],"is_preprint":false},{"year":2023,"finding":"CTSS deletion in mice reduced stress-related carotid artery thrombus formation following FeCl3 induction; mechanistically, CTSS knockout decreased PAI-1, vWF, inflammatory mediators (TNF-α, IL-1β, TLR-4), apoptosis markers (cleaved caspase-3, cytochrome c), oxidative stress markers (gp91phox, p22phox), and MMPs, while increasing ADAMTS13, SOD-1/2, eNOS, p-Akt, Bcl-2, and p-Erk1/2. In vitro, CTSS silencing/overexpression respectively reduced/increased apoptosis of HUVECs exposed to stress serum.","method":"CTSS-/- mice vs. wild-type, FeCl3 carotid thrombosis model, immobilization stress, Western blot, qPCR, pharmacological CTSS inhibition, CTSS siRNA and overexpression in HUVECs","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO + pharmacological inhibition + in vitro gain/loss-of-function, multiple pathway readouts, single lab","pmids":["37128920"],"is_preprint":false},{"year":2023,"finding":"vNAR (Variable New Antigen Receptor) antibody fragments identified by phage display against human proCTSS inhibit CTSS activity by preventing the activation of proCTSS to its mature form (a novel inhibitory mechanism), and can inhibit CTSS activity intracellularly when expressed as intrabodies, reducing tumor cell invasion in vitro.","method":"Phage display panning, ELISA, SPR binding assays, recombinant enzyme activity assays, intrabody expression, tumor cell invasion assay","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 — novel inhibitory mechanism (blocking proenzyme activation) demonstrated by enzyme activity assay, single lab","pmids":["38116078"],"is_preprint":false},{"year":2024,"finding":"Cathepsin S mediates BRCA1 protein degradation in triple-negative breast cancer cells; RT-induced CTSS increase causes radioresistance by suppressing BRCA1-mediated apoptosis. A novel CTSS inhibitor (TS-24) increased BRCA1 protein levels and radiosensitized TNBC cells in vitro and in a xenograft model via BRCA1-mediated apoptosis.","method":"CTSS enzyme assay, in silico docking, Western blot (BRCA1 protein levels), promoter assay, clonogenic survival assay, cell death assay, TNBC xenograft mouse model, immunohistochemistry","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 — substrate relationship (CTSS degrades BRCA1) with in vitro and in vivo pharmacological validation, single lab","pmids":["38613358"],"is_preprint":false},{"year":2024,"finding":"In IBS, enhanced interaction between PDIA3 and STAT3 at the dendritic cell membrane reduces nuclear translocation of phosphorylated STAT3 (p-STAT3), which in turn increases CTSS and MHC-II levels; activated DCs promote CD4+ T cell proliferation and cytokine secretion (IL-4, IL-6, IL-9, TNF-α), contributing to IBS pathology.","method":"Co-IP (PDIA3-STAT3 interaction), Western blot, siRNA PDIA3 knockdown, IBS rat model, punicalagin treatment","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP establishing protein complex, downstream CTSS regulation by p-STAT3 nuclear exclusion, single lab","pmids":["39286134"],"is_preprint":false},{"year":2025,"finding":"Macrophage-derived cathepsin S (CTSS), secreted from choroid plexus (CP) macrophages, is upregulated in aged CP due to increased cell senescence and cleaves the tight junction component claudin 1 (CLDN1), thereby impairing the blood-CSF barrier. Inhibiting CTSS or upregulating CLDN1 in aged CP rejuvenates the blood-CSF barrier and brain functions in aged animals.","method":"CP macrophage isolation, CTSS secretion measurement, in vitro CLDN1 cleavage assay, aged mouse models with CTSS inhibition or CLDN1 overexpression, brain function assessments","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1–2 — direct substrate cleavage (CLDN1) demonstrated biochemically, rescued by CTSS inhibition or CLDN1 upregulation in vivo","pmids":["40015275"],"is_preprint":false},{"year":2025,"finding":"CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma through an Akt-dependent pathway; intratracheal instillation of recombinant CTSS induced neutrophil recruitment and overproduction of soluble E-cadherin (sE-cadherin) in lung tissue, which was attenuated by Akt signaling inhibition; pharmacological CTSS antagonism (LY3000328) decreased airway hyperresponsiveness and neutrophil accumulation and IL-17/sE-cadherin release in murine MGA models.","method":"Recombinant CTSS intratracheal instillation, LY3000328 (CTSS antagonist), Akt inhibition, two murine MGA models (TDI and OVA/CFA), bronchoalveolar lavage cell counts, cytokine measurement","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 — recombinant protein gain-of-function + pharmacological inhibition in two animal models, Akt pathway epistasis, single lab","pmids":["39719614"],"is_preprint":false},{"year":2026,"finding":"Macrophage-derived amphiregulin (AREG) activates EGFR on Schwann cells and upregulates cathepsin S (CTSS) expression, enhancing Schwann cell phagocytic capability for myelin debris clearance after nerve injury; Areg conditional knockout impaired Schwann cell phagocytosis, which was rescued by CTSS restoration.","method":"Areg conditional knockout (cKO) mouse model, conditioned medium experiments, CTSS rescue in Schwann cells, phagocytosis assays, Wallerian degeneration model","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic cKO with CTSS rescue establishing AREG-EGFR-CTSS pathway, functional phagocytosis readout, single lab","pmids":["41708964"],"is_preprint":false}],"current_model":"CTSS encodes a lysosomal cysteine endopeptidase with unusually broad pH activity that is essential for MHC class II antigen presentation (via invariant chain proteolysis to generate αβ-CLIP complexes), cleaves specific extracellular substrates including JAM-B (enabling blood-brain barrier transmigration), CLDN1 (disrupting the blood-CSF barrier), PAR2 (as a biased agonist driving cAMP/TRPV4-dependent pain), IL-36γ (activating this psoriasis cytokine), SLPI, fibronectin (promoting adipogenesis), and BRCA1 (causing radioresistance); its expression is transcriptionally regulated by TFEB (directly binding the CTSS promoter downstream of mTORC1 inhibition) and post-transcriptionally by ADAR1-mediated A-to-I RNA editing that stabilizes CTSS mRNA via HuR recruitment, while secretion is controlled by Rab10/mTORC1-dependent lysosomal exocytosis; intracellularly, CTSS mediates autophagic flux and autophagosome-lysosome fusion in macrophages, promotes M2 polarization of tumor-associated macrophages, and regulates PI3K/AKT/mTOR and JNK signaling in cancer cells."},"narrative":{"teleology":[{"year":1992,"claim":"Cloning of CTSS from human alveolar macrophages established it as a cysteine protease with elastinolytic activity retaining substantial function at neutral pH, distinguishing it from other cathepsins and suggesting extracellular roles.","evidence":"cDNA cloning, recombinant expression in COS cells, active-site labeling, elastin degradation at pH 5.5 and 7.0","pmids":["1373132"],"confidence":"High","gaps":["Crystal structure not yet available at this point","In vivo substrates unknown","Regulatory mechanisms uncharacterized"]},{"year":1996,"claim":"Identification of CTSS as the non-redundant protease required for the final step of invariant chain degradation in antigen-presenting cells resolved a long-standing question about how MHC class II molecules acquire antigenic peptides.","evidence":"Specific small-molecule inhibition in B lymphoblastoid cells causing Ii fragment accumulation; in vitro reconstitution showing only purified CTSS (not cathepsins B, H, or D) generates αβ-CLIP from αβIi trimers","pmids":["8612130"],"confidence":"High","gaps":["Cathepsin S contribution to antigen epitope generation versus Ii processing not yet separated","Role in non-B cell APCs unresolved"]},{"year":1998,"claim":"Subcellular fractionation placed CTSS predominantly in late endosomes and phagosomes of macrophages, while endogenous inhibitors (cystatin C, SCCA1) were characterized kinetically, defining the regulatory framework for CTSS activity in vivo.","evidence":"Organelle fractionation with enzyme activity readouts in J774 macrophages; kinetic inhibition assays with cystatin C mutants and SCCA1–CTSS complex formation","pmids":["9545324","7890620","9548757"],"confidence":"High","gaps":["In vivo relevance of SCCA1 inhibition unclear","Mechanisms controlling CTSS secretion versus retention unknown"]},{"year":2006,"claim":"Demonstration that CTSS degrades extracellular fibronectin to promote preadipocyte differentiation was among the first evidence that CTSS functions outside the endolysosomal compartment in a non-immune, tissue-remodeling context.","evidence":"Primary human preadipocyte cultures treated with recombinant CTSS or specific inhibitor; fibronectin immunostaining and adipocyte marker quantification","pmids":["16825321"],"confidence":"High","gaps":["Fibronectin cleavage site not mapped","Contribution of other secreted cathepsins not fully excluded"]},{"year":2014,"claim":"A burst of substrate discoveries—JAM-B cleavage enabling blood–brain barrier transmigration for breast cancer metastasis, biased agonist cleavage of PAR2 driving cAMP/TRPV4-dependent pain, and a role in autophagy-mediated M2 macrophage polarization—expanded CTSS biology far beyond invariant chain processing.","evidence":"JAM-B: xenograft metastasis models with combined tumor/macrophage CTSS depletion and pharmacological inhibition [PMID:25086747]; PAR2: cleavage site mapping at E56↓T57 with signaling dissection in HEK cells and PAR2/TRPV4-KO mice [PMID:25118282]; autophagy: CTSS-KO mice with mCherry-GFP-LC3 flux assay and TEM [PMID:24580730]","pmids":["25086747","25118282","24580730","24523067","24875536"],"confidence":"High","gaps":["JAM-B cleavage site not precisely mapped","How CTSS enters the autophagy pathway mechanistically is unclear","Whether PAR2 biased agonism by CTSS operates in all tissues unresolved"]},{"year":2016,"claim":"Discovery that ADAR1-mediated A-to-I RNA editing in the CTSS 3′ UTR recruits HuR to stabilize CTSS mRNA revealed a novel post-transcriptional regulatory layer responsive to hypoxia and inflammatory cytokines, explaining CTSS upregulation in atherosclerosis.","evidence":"A-to-I editing sequencing, ADAR1 overexpression, HuR RNA immunoprecipitation, mRNA decay assays in endothelial cells, validation in patient atherosclerotic plaques","pmids":["27595325"],"confidence":"High","gaps":["Whether RNA editing regulation extends to non-endothelial cell types in vivo not established","Identity of factors competing with HuR for unedited CTSS mRNA unknown"]},{"year":2017,"claim":"Identification of CTSS as the major activator of pro-IL-36γ in keratinocytes, generating bioactive IL-36γ-Ser18 that induces psoriasiform changes, directly linked CTSS to psoriasis pathogenesis and a therapeutically actionable substrate.","evidence":"Mass spectrometry cleavage-site identification, siRNA confirmation, functional human skin-equivalent models, elevated CTSS in psoriasis patient samples","pmids":["28289191"],"confidence":"High","gaps":["Whether other cathepsins contribute to IL-36γ activation in vivo not excluded","Clinical efficacy of CTSS inhibitors in psoriasis untested"]},{"year":2020,"claim":"TFEB was identified as a direct transcriptional activator of CTSS downstream of mTORC1 inhibition, while Rab10/mTORC1 signaling controls CTSS secretion via lysosomal exocytosis, establishing a dual transcriptional–secretory regulatory circuit.","evidence":"ChIP-qPCR, EMSA, and luciferase reporter confirming TFEB binding to CTSS promoter; IP-MS identifying Rab10; in vivo atherosclerosis model with CTSS inhibition","pmids":["32640907"],"confidence":"High","gaps":["Whether TFEB regulation of CTSS operates in professional APCs unknown","Rab10-dependent exocytosis mechanism not fully resolved"]},{"year":2025,"claim":"CTSS was shown to cleave claudin-1 (CLDN1) at the choroid plexus, establishing it as a mediator of age-related blood–CSF barrier breakdown; inhibiting CTSS or restoring CLDN1 rejuvenated barrier function and brain cognition in aged mice.","evidence":"Choroid plexus macrophage isolation, in vitro CLDN1 cleavage assay, aged mouse models with CTSS inhibition or CLDN1 overexpression, behavioral assessments","pmids":["40015275"],"confidence":"High","gaps":["CLDN1 cleavage site not precisely defined","Whether senolytic approaches can substitute for direct CTSS inhibition untested","Human translational validation absent"]},{"year":null,"claim":"Key unresolved questions include the full structural basis for CTSS substrate selectivity across its many validated targets, whether CTSS-targeted therapeutics can achieve pathway-selective inhibition without compromising MHC class II-dependent immunity, and how CTSS activity is spatiotemporally coordinated between lysosomal, phagosomal, and extracellular compartments in vivo.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No comprehensive structural model explaining selectivity for diverse substrates","No clinical trial data for CTSS inhibitors addressing therapeutic window","In vivo imaging of CTSS compartment-specific activity lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,6,8,9,10,12,16,21,23]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,3,6,9]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5,17]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[5]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[8,10,16,23,24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,7,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6,10,12,16,21,23]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,14,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,12,14,24]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[17]}],"complexes":[],"partners":["PAR2","CLDN1","JAM-B","TFEB","ADAR1","HUR","BRCA1","RAB10"],"other_free_text":[]},"mechanistic_narrative":"Cathepsin S is a lysosomal cysteine endopeptidase with uniquely broad pH-range activity that serves as the essential protease for MHC class II antigen presentation by cleaving the invariant chain (Ii) to generate αβ-CLIP complexes competent for peptide loading [PMID:8612130, PMID:11884425]. Beyond its canonical immune function, CTSS proteolytically processes diverse extracellular and signaling substrates—including JAM-B (enabling blood–brain barrier transmigration and brain metastasis) [PMID:25086747], claudin-1 (disrupting the blood–CSF barrier during aging) [PMID:40015275], PAR2 (acting as a biased agonist coupling to Gαs/cAMP/TRPV4-dependent pain without β-arrestin recruitment) [PMID:25118282], IL-36γ (generating the bioactive psoriasis cytokine) [PMID:28289191], fibronectin (promoting adipogenesis) [PMID:16825321], SLPI (abolishing anti-elastase protection) [PMID:11435427], and BRCA1 (conferring radioresistance in triple-negative breast cancer) [PMID:38613358]. CTSS expression is transcriptionally controlled by TFEB downstream of mTORC1 inhibition and post-transcriptionally regulated by ADAR1-mediated A-to-I RNA editing that recruits HuR to stabilize CTSS mRNA [PMID:32640907, PMID:27595325]. In macrophages, CTSS promotes autophagic flux and autophagosome–lysosome fusion required for M2 polarization of tumor-associated macrophages, and its secretion is governed by Rab10/mTORC1-dependent lysosomal exocytosis [PMID:24580730, PMID:32640907]."},"prefetch_data":{"uniprot":{"accession":"P25774","full_name":"Cathepsin S","aliases":[],"length_aa":331,"mass_kda":37.5,"function":"Thiol protease (PubMed:30612035). Key protease responsible for the removal of the invariant chain from MHC class II molecules and MHC class II antigen presentation (PubMed:30612035). The bond-specificity of this proteinase is in part similar to the specificities of cathepsin L (PubMed:30612035). Elicits itch by mediating cleavage and activation of MRGPRX1 (By similarity)","subcellular_location":"Lysosome; Secreted; Cytoplasmic vesicle, phagosome","url":"https://www.uniprot.org/uniprotkb/P25774/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CTSS","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CTSS","total_profiled":1310},"omim":[{"mim_id":"604312","title":"CYSTATIN 3; CST3","url":"https://www.omim.org/entry/604312"},{"mim_id":"603253","title":"CYSTATIN 7; CST7","url":"https://www.omim.org/entry/603253"},{"mim_id":"603030","title":"TOLL-LIKE RECEPTOR 4; TLR4","url":"https://www.omim.org/entry/603030"},{"mim_id":"601105","title":"CATHEPSIN K; CTSK","url":"https://www.omim.org/entry/601105"},{"mim_id":"600993","title":"SMAD FAMILY MEMBER 4; SMAD4","url":"https://www.omim.org/entry/600993"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":122.0},{"tissue":"lymphoid tissue","ntpm":127.8}],"url":"https://www.proteinatlas.org/search/CTSS"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P25774","domains":[{"cath_id":"3.90.70.10","chopping":"86-136_151-160_225-331","consensus_level":"high","plddt":96.3699,"start":86,"end":331}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25774","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25774-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25774-F1-predicted_aligned_error_v6.png","plddt_mean":94.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CTSS","jax_strain_url":"https://www.jax.org/strain/search?query=CTSS"},"sequence":{"accession":"P25774","fasta_url":"https://rest.uniprot.org/uniprotkb/P25774.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25774/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25774"}},"corpus_meta":[{"pmid":"35868042","id":"PMC_35868042","title":"Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential.","date":"2022","source":"Molecular aspects of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35868042","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37451150","id":"PMC_37451150","title":"TMT-based quantitative proteomics revealed protective efficacy of Icariside II against airway inflammation and remodeling via inhibiting LAMP2, CTSD and CTSS expression in OVA-induced chronic asthma mice.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37451150","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35732347","id":"PMC_35732347","title":"BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35732347","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31438640","id":"PMC_31438640","title":"Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31438640","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34077394","id":"PMC_34077394","title":"Transfer of exosomal microRNA-203-3p from dendritic cells to bone marrow-derived macrophages reduces development of atherosclerosis by downregulating Ctss in mice.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34077394","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37128920","id":"PMC_37128920","title":"CTSS Modulates Stress-Related Carotid Artery Thrombosis in a Mouse FeCl3 Model.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37128920","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32640907","id":"PMC_32640907","title":"Nicotine Modulates CTSS (Cathepsin S) Synthesis and Secretion Through Regulating the Autophagy-Lysosomal Machinery in Atherosclerosis.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32640907","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36208723","id":"PMC_36208723","title":"Imbalanced IL-37/TNF-α/CTSS signaling disrupts corneal epithelial barrier in a dry eye model in vitro.","date":"2022","source":"The ocular surface","url":"https://pubmed.ncbi.nlm.nih.gov/36208723","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34208434","id":"PMC_34208434","title":"Skullcapflavone II Suppresses TNF-α/IFN-γ-Induced TARC, MDC, and CTSS Production in HaCaT Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34208434","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30341237","id":"PMC_30341237","title":"Association between CTSS gene polymorphism and the risk of acute atherosclerotic cerebral infarction in Chinese population: a case-control study.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30341237","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40015275","id":"PMC_40015275","title":"Macrophage-derived CTSS drives the age-dependent disruption of the blood-CSF barrier.","date":"2025","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/40015275","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22844403","id":"PMC_22844403","title":"Dietary factors impact on the association between CTSS variants and obesity related traits.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22844403","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32176315","id":"PMC_32176315","title":"MiR-491-3p is down-regulated in postmenopausal osteoporosis and affects growth, differentiation and apoptosis of hFOB1.19 cells through targeting CTSS.","date":"2020","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/32176315","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34199180","id":"PMC_34199180","title":"Modulation of Cathepsin S (CTSS) Regulates the Secretion of Progesterone and Estradiol, Proliferation, and Apoptosis of Ovarian Granulosa Cells in Rabbits.","date":"2021","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/34199180","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38613358","id":"PMC_38613358","title":"Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/38613358","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20374908","id":"PMC_20374908","title":"Association between cathepsin L (CTSL) and cathepsin S (CTSS) polymorphisms and meat production and carcass traits in Italian Large White pigs.","date":"2010","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/20374908","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32315741","id":"PMC_32315741","title":"Genome-wide identification, expression signature and immune functional analysis of two cathepsin S (CTSS) genes in turbot (Scophthalmus maximus L.).","date":"2020","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32315741","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10721671","id":"PMC_10721671","title":"Human cathepsin S gene (CTSS) promoter -25G/A polymorphism.","date":"2000","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10721671","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16452791","id":"PMC_16452791","title":"CTSS: a robust and efficient method for protein structure alignment based on local geometrical and biological features.","date":"2003","source":"Proceedings. IEEE Computer Society Bioinformatics Conference","url":"https://pubmed.ncbi.nlm.nih.gov/16452791","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39972407","id":"PMC_39972407","title":"Bioinformatics-based identification of CTSS, DOK2, and ENTPD1 as potential blood biomarkers of schizophrenia.","date":"2025","source":"BMC psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/39972407","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29447938","id":"PMC_29447938","title":"Hypothesis: Is there a link between the immune response to Human Herpes Virus type 6Α (HHV-6Α) infection and the interaction network (interactome) of the genes encoding the CTSS, PTX3, CHI3L1, Mx1, CXCL16, BIRC3 and BST2 proteins?","date":"2018","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/29447938","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38979419","id":"PMC_38979419","title":"Cathepsin S (CTSS) in IgA nephropathy: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38979419","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38089704","id":"PMC_38089704","title":"Effect of CTSS non-synonymous mutations on litter size in Qianbei Ma goats.","date":"2023","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/38089704","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37801777","id":"PMC_37801777","title":"Noise exposure increase apoptosis in the hippocampus of AD mice through the upregulation of CTSS.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37801777","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39719614","id":"PMC_39719614","title":"CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma.","date":"2024","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/39719614","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40557874","id":"PMC_40557874","title":"Maraviroc Prevents Optic Nerve Injury-Induced Retinal Ganglion Cell Apoptosis by Modulating the CCL5/CCR5/CTSS Axis.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/40557874","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40461927","id":"PMC_40461927","title":"Identifying a gene signature for age-related hearing loss through machine learning and revealing the effect of the CTSS on the mice cochlea.","date":"2025","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/40461927","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38116078","id":"PMC_38116078","title":"Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38116078","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39824912","id":"PMC_39824912","title":"Integrative genetics and multiomics analysis reveal mechanisms and therapeutic targets in vitiligo highlighting JAK STAT pathway regulation of CTSS.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39824912","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39286134","id":"PMC_39286134","title":"The PDIA3-STAT3 protein complex regulates IBS formation and development via CTSS/MHC-II pathway-mediated intestinal inflammation.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39286134","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19593952","id":"PMC_19593952","title":"CTSS promoter -25G/A: not a risk factor for CHD in Chinese.","date":"2009","source":"Acta cardiologica","url":"https://pubmed.ncbi.nlm.nih.gov/19593952","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40624623","id":"PMC_40624623","title":"CTSS and CD53: Emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implications.","date":"2025","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/40624623","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40965405","id":"PMC_40965405","title":"LINC02099 Promotes Retinal Extracellular Matrix Deposition in Diabetic Mice Via the miRNA-214-3p/CTSS Axis.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/40965405","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38914301","id":"PMC_38914301","title":"Potential role of CTSS in AMDImmune modulatory and anti-angiogenic effects of cathepsin S knockdown in ARPE-19 cells.","date":"2024","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/38914301","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41708964","id":"PMC_41708964","title":"Macrophage-Derived Amphiregulin Enhances Schwann Cell Phagocytosis Through the EGFR/CTSS Signaling Pathway.","date":"2026","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/41708964","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40730712","id":"PMC_40730712","title":"CTSS in the tumor microenvironment links immune escape and immunotherapy sensitivity in kidney renal clear cell carcinoma.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40730712","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40251967","id":"PMC_40251967","title":"Genetic and functional validation of CTSS in regulating intramuscular fat content of Duroc-Landrace-Yorkshire pigs.","date":"2025","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40251967","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41993107","id":"PMC_41993107","title":"Single-Cell Transcriptomics Reveals Riluzole as an Osteoarthritis Candidate Drug via OB-NE Signaling Modulation and CTSS/NOS1 Inhibition.","date":"2026","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41993107","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.01.685128","title":"Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer","date":"2025-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.01.685128","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.20.627872","title":"Genome-wide mapping of the <i>Galleria mellonella</i> larvae transcription start sites during fungal infection and treatment","date":"2025-01-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.20.627872","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8612130","id":"PMC_8612130","title":"Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8612130","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25086747","id":"PMC_25086747","title":"Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.","date":"2014","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25086747","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1373132","id":"PMC_1373132","title":"Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1373132","citation_count":260,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9548757","id":"PMC_9548757","title":"Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9548757","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27595325","id":"PMC_27595325","title":"Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation.","date":"2016","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27595325","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25037231","id":"PMC_25037231","title":"Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25037231","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24523067","id":"PMC_24523067","title":"Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24523067","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8157683","id":"PMC_8157683","title":"Human cathepsin S: chromosomal localization, gene structure, and tissue distribution.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8157683","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9545324","id":"PMC_9545324","title":"Lysosomal enzyme trafficking between phagosomes, endosomes, and lysosomes in J774 macrophages. Enrichment of cathepsin H in early endosomes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9545324","citation_count":160,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25118282","id":"PMC_25118282","title":"Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25118282","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21967108","id":"PMC_21967108","title":"Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S.","date":"2011","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/21967108","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11435427","id":"PMC_11435427","title":"Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11435427","citation_count":152,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16710414","id":"PMC_16710414","title":"The DNA sequence and biological annotation of human chromosome 1.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16710414","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11884425","id":"PMC_11884425","title":"A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11884425","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24875536","id":"PMC_24875536","title":"Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.","date":"2014","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24875536","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28289191","id":"PMC_28289191","title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28289191","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16825321","id":"PMC_16825321","title":"Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16825321","citation_count":115,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18029348","id":"PMC_18029348","title":"Toward a confocal subcellular atlas of the human proteome.","date":"2007","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18029348","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24580730","id":"PMC_24580730","title":"Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24580730","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7890620","id":"PMC_7890620","title":"Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7890620","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24644101","id":"PMC_24644101","title":"Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.","date":"2014","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24644101","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7717452","id":"PMC_7717452","title":"The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study.","date":"1995","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7717452","citation_count":100,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11241311","id":"PMC_11241311","title":"Expression of cathepsins B and S in the progression of prostate carcinoma.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11241311","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":22869,"output_tokens":3475,"usd":0.060366},"stage2":{"model":"claude-opus-4-6","input_tokens":6879,"output_tokens":3440,"usd":0.180592},"total_usd":0.546482,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":37378,"output_tokens":7032,"usd":0.108807},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10994,"output_tokens":3047,"usd":0.196717}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Macrophage-derived CTSS, upregulated in aged choroid plexus due to increased cell senescence, directly cleaves the tight junction component claudin 1 (CLDN1), thereby impairing the blood-CSF barrier. Inhibiting CTSS or upregulating CLDN1 in aged choroid plexus rejuvenates the blood-CSF barrier and brain functions.\",\n      \"method\": \"In vivo CTSS inhibition, CLDN1 overexpression in aged mice, biochemical cleavage assays, fractionation/localization studies, functional readouts of CSF barrier integrity\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (genetic inhibition, substrate identification, functional rescue) in a single study with clear mechanistic chain\",\n      \"pmids\": [\"40015275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nicotine inhibits mTORC1 activity, promotes nuclear translocation of TFEB, and TFEB directly binds the CTSS promoter to upregulate CTSS expression in vascular smooth muscle cells. mTORC1 inhibition also promotes lysosomal exocytosis and CTSS secretion via a mechanism involving Rab10-mTORC1 interactions. CTSS upregulation mediates nicotine-induced vascular smooth muscle cell migration and atherosclerosis progression.\",\n      \"method\": \"ChIP-qPCR, EMSA, luciferase reporter assay, Western blotting, immunofluorescent staining, live cell assays, IP-MS, in vivo CTSS inhibition in atherosclerosis model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP, EMSA, reporter assay, IP-MS, and in vivo validation\",\n      \"pmids\": [\"32640907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma through an Akt-dependent pathway; intratracheal instillation of recombinant CTSS leads to neutrophil recruitment and overproduction of soluble E-cadherin (sE-cadherin), and Akt inhibition attenuates these effects.\",\n      \"method\": \"Pharmacological CTSS antagonism (LY3000328) in murine MGA models, intratracheal recombinant CTSS instillation, Akt inhibitor co-treatment, in vivo airway inflammatory readouts\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo KO/inhibition with defined cellular phenotype and pathway placement via Akt inhibitor rescue\",\n      \"pmids\": [\"39719614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSS activity in macrophages and dendritic cells mediates enhanced antigen processing and presentation of tumor-associated antigens; BCG lysate hydrogel promotes CTSS activity in these cells, resulting in increased CD8+ T cell responses.\",\n      \"method\": \"scRNA-seq of tumor-infiltrating immune cells, CTSS activity assays in macrophages/DCs, in vivo syngeneic tumor models, human biopsy RNA-seq validation\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional CTSS activity assay linked to antigen presentation outcome with in vivo and human data\",\n      \"pmids\": [\"35732347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTSS deficiency in a mouse FeCl3 carotid thrombosis model reduces stress-related thrombosis by decreasing vascular inflammation, oxidative stress, and apoptosis; CTSS silencing reduced and overexpression increased apoptosis-related proteins in human umbilical vein endothelial cells under oxidative stress.\",\n      \"method\": \"CTSS knockout mice, pharmacological CTSS inhibition, in vitro CTSS silencing/overexpression in HUVECs, FeCl3-induced thrombosis model, biochemical assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype plus in vitro mechanistic validation with gain/loss of function\",\n      \"pmids\": [\"37128920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RT-induced increase in CTSS causes radioresistance in triple-negative breast cancer through CTSS-mediated degradation of BRCA1 protein, suppressing BRCA1-mediated apoptosis. A novel CTSS inhibitor (TS-24) increased BRCA1 protein levels and showed radiosensitization in TNBC cells in vitro and in vivo.\",\n      \"method\": \"Western blotting, promoter assay, cell death assay, clonogenic survival assay, xenograft mouse model, CTSS enzyme assay, in silico docking\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — substrate identification (BRCA1 degradation by CTSS) with functional rescue in vitro and in vivo\",\n      \"pmids\": [\"38613358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Dendritic cell-derived exosomal miR-203-3p targets CTSS (directly downregulating it) in bone marrow-derived macrophages, reducing foam-cell formation, lipid accumulation, and atherosclerosis via the p38/MAPK signaling pathway.\",\n      \"method\": \"Exosome isolation, gain/loss-of-function experiments in macrophages, atherosclerosis mouse models, luciferase target validation, p38/MAPK pathway analysis\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct target validation plus in vivo pathway placement, single lab\",\n      \"pmids\": [\"34077394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSS directly disrupts epithelial barrier integrity in corneal epithelial cells; TNF-α and hyperosmolarity induce CTSS expression, and IL-37 suppresses TNF-α and CTSS expression, thereby protecting tight junction integrity (ZO-1, occludin, claudin-1, E-cadherin).\",\n      \"method\": \"Primary human corneal epithelial cell culture, hyperosmolar stress model, RT-qPCR, ELISA, immunofluorescent staining with confocal microscopy, rhIL-37 and rhTNF-α treatment\",\n      \"journal\": \"The ocular surface\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct functional link between CTSS activity and barrier disruption with cytokine regulation demonstrated by multiple methods\",\n      \"pmids\": [\"36208723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"vNAR antibody fragments (vNARs) inhibit CTSS activity by a novel mechanism: preventing activation of proCTSS to the mature enzyme, rather than blocking the active enzyme. Intrabody expression of vNARs inhibits CTSS activity intracellularly and impedes tumor cell invasion.\",\n      \"method\": \"Phage display, recombinant protein binding (ELISA, SPR), CTSS enzyme activity assays, intrabody expression, tumor cell invasion assay\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzyme assay with mechanistic elucidation of inhibitory mechanism (proCTSS activation block), functional validation in cell invasion\",\n      \"pmids\": [\"38116078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In dendritic cells from IBS patients, heightened PDIA3-STAT3 interaction at the DC membrane reduces nuclear translocation of p-STAT3, which in turn increases CTSS and MHC-II levels, promoting CD4+ T cell proliferation and cytokine secretion.\",\n      \"method\": \"Co-IP/interaction assays, protein localization studies, knockdown experiments, cytokine measurement, rat IBS model\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic pathway proposed with limited direct biochemical validation of CTSS's specific role\",\n      \"pmids\": [\"39286134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fisetin inhibits migration and invasion of renal cell carcinoma cells through MEK/ERK pathway-mediated downregulation of CTSS and ADAM9; MEK inhibitor (UO126) reduces the inhibitory effects of fisetin on RCC metastasis through the ERK/CTSS/ADAM9 pathway.\",\n      \"method\": \"Cell migration/invasion assays, human protease antibody array, Western blotting, RT-qPCR, MEK inhibitor epistasis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement of CTSS downstream of MEK/ERK with pharmacological epistasis and multiple readouts\",\n      \"pmids\": [\"31438640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTSS knockdown in ARPE-19 retinal pigment epithelial cells reduces oxidative stress-induced NF-κB-dependent inflammatory cytokines, complement factors C3a and C5a, and membrane attack complex expression, and attenuates angiogenesis via effects on PPARγ and VEGF-A/Akt signaling.\",\n      \"method\": \"siRNA knockdown, H2O2 oxidative stress model, tube formation assay in HUVECs, laser-induced choroidal neovascularization mouse model\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined molecular phenotype using multiple pathways and in vivo validation\",\n      \"pmids\": [\"38914301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Macrophage-secreted amphiregulin (AREG) activates EGFR on Schwann cells and upregulates CTSS expression, which enhances Schwann cell phagocytic capability for myelin debris clearance after nerve injury. CTSS restoration rescued phagocytic defects in Schwann cells treated with conditioned medium from Areg conditional knockout macrophages.\",\n      \"method\": \"Areg conditional knockout mouse model, conditioned medium experiments, CTSS rescue assay, phagocytosis functional readouts\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with rescue experiment identifies AREG-EGFR-CTSS axis in Schwann cell phagocytosis\",\n      \"pmids\": [\"41708964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LINC02099 acts as a competing endogenous RNA (ceRNA) that sponges miR-214-3p; CTSS is a direct target of miR-214-3p, and CTSS knockdown attenuates high-glucose-induced extracellular matrix deposition (fibronectin, collagen I, collagen IV) in Müller cells. In vivo, LINC02099 overexpression aggravates ECM deposition in retinas of diabetic mice via the miR-214-3p/CTSS axis.\",\n      \"method\": \"FISH, dual-luciferase reporter assay, siRNA knockdown, miRNA mimic, in vivo diabetic mouse model, Western blotting, immunofluorescence\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct miR-CTSS interaction validated by luciferase assay with in vivo confirmation\",\n      \"pmids\": [\"40965405\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTSS (Cathepsin S) is a lysosomal cysteine endopeptidase that, beyond general lysosomal protein degradation, mediates antigen processing and MHC class II presentation in macrophages and dendritic cells, cleaves specific extracellular substrates including claudin-1 (disrupting the blood-CSF barrier) and BRCA1, promotes vascular smooth muscle cell migration downstream of a TFEB-mediated transcriptional program induced by mTORC1 inhibition, drives airway neutrophilic inflammation via Akt-dependent E-cadherin shedding, and is secreted from lysosomes via Rab10/mTORC1-regulated lysosomal exocytosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"Human cathepsin S (CTSS) was cloned from alveolar macrophage cDNA and shown to encode a 28-kDa cysteine protease with elastinolytic activity, retaining ~25% of its pH 5.5 elastinolytic activity at pH 7.0, indicating broad pH range activity unlike other cathepsins.\",\n      \"method\": \"cDNA cloning, COS cell expression, active-site labeling with iodinated E-64 analogue, in vitro elastin degradation assay, Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted recombinant enzyme activity, active-site labeling, founding paper replicated by subsequent studies\",\n      \"pmids\": [\"1373132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CTSS gene was mapped to chromosome 1q21 by fluorescence in situ hybridization; the gene structure resembles cathepsin L through exons 1–5 but has larger introns; 5'-flanking region contains AP1 sites and CA microsatellites but no TATA or CAAT box; tissue distribution is restricted (highest in spleen, heart, lung) with immunostaining detecting CTSS only in lung macrophages.\",\n      \"method\": \"Genomic library screening, FISH, Northern blotting, immunostaining\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct genomic mapping and tissue localization with multiple orthogonal methods\",\n      \"pmids\": [\"8157683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Cystatin C inhibits cathepsin S with a Ki ~10⁻⁸ M even when the key N-terminal Leu-9 side chain (which contributes 200-fold to cathepsin B affinity and 50-fold to cathepsin L affinity) is absent, demonstrating that the structural determinants for cystatin C selectivity differ between cathepsin S and other cathepsins.\",\n      \"method\": \"Site-directed mutagenesis of cystatin C variants, kinetic inhibition assays against cathepsins B, H, L, S\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted inhibition with mutagenesis, rigorous kinetic analysis\",\n      \"pmids\": [\"7890620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Cathepsin S is essential for complete proteolysis of the MHC class II-associated invariant chain (Ii) in B lymphoblastoid cells; specific CTSS inhibition caused accumulation of a 13 kDa Ii fragment, reduced SDS-stable class II complexes, and prevented peptide loading. Purified cathepsin S (but not cathepsins B, H, or D) specifically digested Ii from αβIi trimers in vitro to generate αβ-CLIP complexes capable of binding exogenous peptide.\",\n      \"method\": \"Specific small-molecule inhibition in B cells, in vitro reconstitution with purified cathepsins, Western blot, peptide-binding assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified enzyme + cell-based inhibitor studies, foundational paper with high citation count\",\n      \"pmids\": [\"8612130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCCA1 (serpin squamous cell carcinoma antigen 1) is a potent cross-class inhibitor of cathepsin S, forming stable complexes (t½ > 1155 min) via cleavage between Gly and Ser in its reactive-site loop, analogous to serpin–serine protease interactions; interaction with cathepsin S is 1:1 stoichiometry with second-order rate constants ≥1×10⁵ M⁻¹s⁻¹.\",\n      \"method\": \"Kinetic inhibition assays, SDS-PAGE complex detection, reactive-site loop cleavage mapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous kinetic analysis with purified proteins, multiple methods\",\n      \"pmids\": [\"9548757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In J774 macrophages, the bulk of cellular cathepsin S is concentrated in late endosomes (as opposed to cathepsin H enriched in early endosomes), and cathepsin S is present in phagosomal fractions, establishing its trafficking itinerary within the endolysosomal system.\",\n      \"method\": \"Subcellular fractionation, enrichment of early endosomes/late endosomes/lysosomes/phagosomes, enzyme activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular fractionation with functional activity readout, rigorous organelle enrichment\",\n      \"pmids\": [\"9545324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Cathepsin S (along with B and L) cleaves and inactivates secretory leucoprotease inhibitor (SLPI) between Thr67 and Tyr68, eliminating SLPI's active site and its anti-neutrophil elastase capacity; cathepsins L and S inactivated a 400-fold excess of SLPI within 15 min in catalytic fashion.\",\n      \"method\": \"In vitro cleavage assay with purified cathepsins, sequencing of cleavage site, anti-elastase activity assay, analysis of emphysema epithelial lining fluid\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with cleavage site identified, confirmed in patient samples\",\n      \"pmids\": [\"11435427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cathepsin S expressed in embryonic fibroblasts mediates invariant chain degradation and alters the peptide repertoire presented by MHC class II molecules; for a subset of antigens, cathepsin S is required for epitope generation, as shown by T cell hybridoma assays and mass spectrometric analysis of eluted peptides.\",\n      \"method\": \"Reconstituted fibroblast cell lines expressing cathepsin L or S, T cell hybridoma assays, mass spectrometry of MHC II-eluted peptides\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted system with multiple readouts including mass spectrometry and functional T cell assay\",\n      \"pmids\": [\"11884425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cathepsin S promotes human preadipocyte differentiation at least in part by degrading fibronectin in the extracellular matrix; CTSS activity was highest in preadipocyte culture medium and decreased during differentiation; exogenous recombinant CTSS increased adipogenesis and markedly reduced the fibronectin network, while specific CTSS inhibition reduced lipid content and adipocyte marker expression 2-fold.\",\n      \"method\": \"Primary human preadipocyte cultures, recombinant CTSS treatment, specific inhibitor treatment, fibronectin immunostaining, adipocyte marker expression\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with recombinant protein and inhibitor, multiple readouts, replicated in tissue sections\",\n      \"pmids\": [\"16825321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Proteomic identification of cathepsin S cleavage sites (PICS) at pH 6.0 and 7.5 revealed that its specificity is primarily guided by aliphatic residues in P2, with limited importance of prime-site residues; the specificity profiles at both pH values were highly similar, consistent with broad pH activity.\",\n      \"method\": \"PICS (proteomic identification of protease cleavage sites) with mass spectrometry at pH 6.0 and 7.5\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive substrate profiling by mass spectrometry at two pH conditions\",\n      \"pmids\": [\"21967108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin S specifically mediates breast-to-brain metastasis by proteolytic processing of the junctional adhesion molecule JAM-B, enabling blood-brain barrier transmigration; both macrophage- and tumor cell-derived CTSS contribute, and only combined depletion significantly reduced brain metastasis in vivo; pharmacological inhibition of CTSS significantly reduced experimental brain metastasis.\",\n      \"method\": \"Xenograft metastasis models (xenograft), CTSS depletion from tumor cells and macrophages separately and combined, in vitro BBB transmigration assay, proteolytic substrate identification (JAM-B cleavage), pharmacological inhibition in vivo\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — substrate identification (JAM-B cleavage) with in vivo validation, epistasis via combined depletion, pharmacological confirmation\",\n      \"pmids\": [\"25086747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD47-positive hepatocellular carcinoma (HCC) tumor-initiating cells preferentially secrete cathepsin S, which regulates liver tumor-initiating cell properties through a CTSS/protease-activated receptor 2 (PAR2) signaling loop; knockdown of CD47 suppressed this CTSS/PAR2 axis and reduced HCC growth in vivo.\",\n      \"method\": \"CD47 knockdown (morpholino), CTSS secretion measurement, PAR2 signaling assays, in vivo HCC tumor models\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function linking CD47/CTSS/PAR2 pathway with in vivo validation\",\n      \"pmids\": [\"24523067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin S cleaves PAR2 at E56↓T57 (distinct from the canonical trypsin site R36↓S37), acting as a biased agonist: it stimulates PAR2 coupling to Gαs/cAMP but does not mobilize intracellular Ca²⁺, activate ERK1/2, recruit β-arrestins, or induce PAR2 endocytosis. Cat-S causes PAR2- and TRPV4-dependent inflammation and hyperalgesia via adenylyl cyclase/PKA mechanisms in mouse dorsal root ganglia and in vivo.\",\n      \"method\": \"In vitro cleavage site mapping, HEK/KNRK cell signaling assays (cAMP, Ca²⁺, ERK, β-arrestin), Xenopus oocyte electrophysiology, mouse DRG nociceptor recordings, PAR2/TRPV4 knockout mice, intraplantar injection model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cleavage site identified biochemically, biased signaling demonstrated with multiple orthogonal assays, confirmed in KO mice in vivo\",\n      \"pmids\": [\"25118282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin S is required for autophagic flux (including autophagosome-lysosome fusion) in tumor-associated macrophages (TAMs); CTSS knockout inhibited M2 macrophage polarization during tumor development and reduced tumor growth and metastasis; Cat S promotes M2 polarization through activation of autophagy.\",\n      \"method\": \"Cat S knockout mice, subcutaneous and hepatic metastasis tumor models, mCherry-GFP-LC3 autophagy flux assay, DQ-BSA degradation, TEM, flow cytometry for macrophage phenotype\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple in vivo and in vitro mechanistic readouts including autophagy flux assays\",\n      \"pmids\": [\"24580730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Inhibition of cathepsin S in glioblastoma cells induces autophagy and mitochondrial apoptosis via ROS-mediated suppression of the PI3K/AKT/mTOR/p70S6K pathway and activation of JNK signaling; blocking autophagy attenuated cathepsin S inhibition-induced apoptosis, placing autophagy upstream of apoptosis in this pathway.\",\n      \"method\": \"Small-molecule CTSS inhibition, siRNA knockdown, ROS measurement, Western blot for PI3K/AKT/mTOR/JNK pathway components, autophagy inhibitors, cell death assays\",\n      \"journal\": \"Toxicology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pharmacological and siRNA approaches with pathway epistasis, single lab\",\n      \"pmids\": [\"24875536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CTSS mRNA is highly edited at its 3' UTR by ADAR1 via adenosine-to-inosine (A-to-I) RNA editing within AluJo/AluSx+ inverted repeat elements that form a long stem-loop; editing enables recruitment of the stabilizing RNA-binding protein HuR to the CTSS 3' UTR, controlling CTSS mRNA stability and expression. Hypoxia and inflammatory cytokines (IFN-γ, TNF-α) induce CTSS RNA editing and increase cathepsin S expression in endothelial cells.\",\n      \"method\": \"A-to-I editing sequencing, ADAR1 overexpression, RIP (RNA immunoprecipitation) of HuR, mRNA stability assays, patient atherosclerosis samples, cytokine treatment\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic epitranscriptomic regulation established with multiple orthogonal methods, validated in patient samples\",\n      \"pmids\": [\"27595325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ in keratinocytes; CTSS cleaves pro-IL-36γ to generate the bioactive form IL-36γ-Ser18; this product induces psoriasiform changes in human skin-equivalent models; CTSS activity is strongly upregulated in psoriasis patient samples.\",\n      \"method\": \"Keratinocyte activity assay, small-molecule inhibitors, siRNA gene silencing, mass spectrometry cleavage-site identification, human skin-equivalent models, patient psoriasis samples\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — substrate cleavage site mapped biochemically, siRNA confirmation, functional skin model, patient validation\",\n      \"pmids\": [\"28289191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nicotine activates autophagy in vascular smooth muscle cells by inhibiting mTORC1 activity, promoting nuclear translocation of TFEB, which directly binds the CTSS promoter (demonstrated by ChIP-qPCR, EMSA, and luciferase reporter assay) to upregulate CTSS expression. mTORC1 inhibition promotes lysosomal exocytosis and CTSS secretion via a mechanism involving Rab10; CTSS upregulation promotes vascular smooth muscle cell migration and atherosclerosis in vivo.\",\n      \"method\": \"Western blot, immunofluorescent staining, ChIP-qPCR, EMSA, luciferase reporter assay, IP-MS (Rab10 interaction), live cell imaging, in vivo atherosclerosis model with CTSS inhibition\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct TFEB-CTSS promoter binding proven by three orthogonal methods, Rab10-mTORC1 interaction by IP-MS, in vivo confirmation\",\n      \"pmids\": [\"32640907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSS directly disrupts epithelial barrier integrity in corneal epithelial cells; TNF-α and hyperosmolarity induce CTSS expression, while IL-37 suppresses TNF-α and CTSS expression and restores tight junction (ZO-1, occludin, claudin-1) and adherens junction (E-cadherin) protein integrity under hyperosmotic stress.\",\n      \"method\": \"Primary human corneal epithelial cell culture, hyperosmolar stress model, RT-qPCR, ELISA, immunofluorescent confocal microscopy, rhIL-37 and rhTNF-α treatment\",\n      \"journal\": \"The ocular surface\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cell-based model with direct barrier protein readout, mechanistic pathway defined, single lab\",\n      \"pmids\": [\"36208723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTSS deletion in mice reduced stress-related carotid artery thrombus formation following FeCl3 induction; mechanistically, CTSS knockout decreased PAI-1, vWF, inflammatory mediators (TNF-α, IL-1β, TLR-4), apoptosis markers (cleaved caspase-3, cytochrome c), oxidative stress markers (gp91phox, p22phox), and MMPs, while increasing ADAMTS13, SOD-1/2, eNOS, p-Akt, Bcl-2, and p-Erk1/2. In vitro, CTSS silencing/overexpression respectively reduced/increased apoptosis of HUVECs exposed to stress serum.\",\n      \"method\": \"CTSS-/- mice vs. wild-type, FeCl3 carotid thrombosis model, immobilization stress, Western blot, qPCR, pharmacological CTSS inhibition, CTSS siRNA and overexpression in HUVECs\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pharmacological inhibition + in vitro gain/loss-of-function, multiple pathway readouts, single lab\",\n      \"pmids\": [\"37128920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"vNAR (Variable New Antigen Receptor) antibody fragments identified by phage display against human proCTSS inhibit CTSS activity by preventing the activation of proCTSS to its mature form (a novel inhibitory mechanism), and can inhibit CTSS activity intracellularly when expressed as intrabodies, reducing tumor cell invasion in vitro.\",\n      \"method\": \"Phage display panning, ELISA, SPR binding assays, recombinant enzyme activity assays, intrabody expression, tumor cell invasion assay\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — novel inhibitory mechanism (blocking proenzyme activation) demonstrated by enzyme activity assay, single lab\",\n      \"pmids\": [\"38116078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cathepsin S mediates BRCA1 protein degradation in triple-negative breast cancer cells; RT-induced CTSS increase causes radioresistance by suppressing BRCA1-mediated apoptosis. A novel CTSS inhibitor (TS-24) increased BRCA1 protein levels and radiosensitized TNBC cells in vitro and in a xenograft model via BRCA1-mediated apoptosis.\",\n      \"method\": \"CTSS enzyme assay, in silico docking, Western blot (BRCA1 protein levels), promoter assay, clonogenic survival assay, cell death assay, TNBC xenograft mouse model, immunohistochemistry\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — substrate relationship (CTSS degrades BRCA1) with in vitro and in vivo pharmacological validation, single lab\",\n      \"pmids\": [\"38613358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In IBS, enhanced interaction between PDIA3 and STAT3 at the dendritic cell membrane reduces nuclear translocation of phosphorylated STAT3 (p-STAT3), which in turn increases CTSS and MHC-II levels; activated DCs promote CD4+ T cell proliferation and cytokine secretion (IL-4, IL-6, IL-9, TNF-α), contributing to IBS pathology.\",\n      \"method\": \"Co-IP (PDIA3-STAT3 interaction), Western blot, siRNA PDIA3 knockdown, IBS rat model, punicalagin treatment\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP establishing protein complex, downstream CTSS regulation by p-STAT3 nuclear exclusion, single lab\",\n      \"pmids\": [\"39286134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Macrophage-derived cathepsin S (CTSS), secreted from choroid plexus (CP) macrophages, is upregulated in aged CP due to increased cell senescence and cleaves the tight junction component claudin 1 (CLDN1), thereby impairing the blood-CSF barrier. Inhibiting CTSS or upregulating CLDN1 in aged CP rejuvenates the blood-CSF barrier and brain functions in aged animals.\",\n      \"method\": \"CP macrophage isolation, CTSS secretion measurement, in vitro CLDN1 cleavage assay, aged mouse models with CTSS inhibition or CLDN1 overexpression, brain function assessments\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct substrate cleavage (CLDN1) demonstrated biochemically, rescued by CTSS inhibition or CLDN1 upregulation in vivo\",\n      \"pmids\": [\"40015275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma through an Akt-dependent pathway; intratracheal instillation of recombinant CTSS induced neutrophil recruitment and overproduction of soluble E-cadherin (sE-cadherin) in lung tissue, which was attenuated by Akt signaling inhibition; pharmacological CTSS antagonism (LY3000328) decreased airway hyperresponsiveness and neutrophil accumulation and IL-17/sE-cadherin release in murine MGA models.\",\n      \"method\": \"Recombinant CTSS intratracheal instillation, LY3000328 (CTSS antagonist), Akt inhibition, two murine MGA models (TDI and OVA/CFA), bronchoalveolar lavage cell counts, cytokine measurement\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — recombinant protein gain-of-function + pharmacological inhibition in two animal models, Akt pathway epistasis, single lab\",\n      \"pmids\": [\"39719614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Macrophage-derived amphiregulin (AREG) activates EGFR on Schwann cells and upregulates cathepsin S (CTSS) expression, enhancing Schwann cell phagocytic capability for myelin debris clearance after nerve injury; Areg conditional knockout impaired Schwann cell phagocytosis, which was rescued by CTSS restoration.\",\n      \"method\": \"Areg conditional knockout (cKO) mouse model, conditioned medium experiments, CTSS rescue in Schwann cells, phagocytosis assays, Wallerian degeneration model\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic cKO with CTSS rescue establishing AREG-EGFR-CTSS pathway, functional phagocytosis readout, single lab\",\n      \"pmids\": [\"41708964\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTSS encodes a lysosomal cysteine endopeptidase with unusually broad pH activity that is essential for MHC class II antigen presentation (via invariant chain proteolysis to generate αβ-CLIP complexes), cleaves specific extracellular substrates including JAM-B (enabling blood-brain barrier transmigration), CLDN1 (disrupting the blood-CSF barrier), PAR2 (as a biased agonist driving cAMP/TRPV4-dependent pain), IL-36γ (activating this psoriasis cytokine), SLPI, fibronectin (promoting adipogenesis), and BRCA1 (causing radioresistance); its expression is transcriptionally regulated by TFEB (directly binding the CTSS promoter downstream of mTORC1 inhibition) and post-transcriptionally by ADAR1-mediated A-to-I RNA editing that stabilizes CTSS mRNA via HuR recruitment, while secretion is controlled by Rab10/mTORC1-dependent lysosomal exocytosis; intracellularly, CTSS mediates autophagic flux and autophagosome-lysosome fusion in macrophages, promotes M2 polarization of tumor-associated macrophages, and regulates PI3K/AKT/mTOR and JNK signaling in cancer cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CTSS (Cathepsin S) is a lysosomal cysteine endopeptidase that functions in antigen processing, extracellular matrix remodeling, and epithelial barrier regulation across immune, vascular, and neural tissues. In macrophages and dendritic cells, CTSS mediates MHC class II-dependent antigen processing and presentation, promoting adaptive immune responses including CD8+ and CD4+ T cell activation [PMID:35732347, PMID:39286134]; it also cleaves tight junction proteins such as claudin-1, disrupting the blood-CSF barrier during aging and corneal epithelial integrity under inflammatory stress [PMID:40015275, PMID:36208723]. CTSS is transcriptionally upregulated by TFEB upon mTORC1 inhibition and secreted via Rab10-dependent lysosomal exocytosis, driving vascular smooth muscle cell migration and atherosclerosis progression [PMID:32640907], and its proteolytic activity extends to substrates including BRCA1, whose CTSS-mediated degradation confers radioresistance in triple-negative breast cancer [PMID:38613358]. Extracellularly, CTSS promotes neutrophilic airway inflammation through Akt-dependent E-cadherin shedding and contributes to oxidative stress-induced vascular thrombosis and choroidal neovascularization via NF-κB and VEGF-A/Akt signaling [PMID:39719614, PMID:37128920, PMID:38914301].\",\n  \"teleology\": [\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing that CTSS expression is regulated by the MEK/ERK signaling pathway placed CTSS downstream of a major mitogenic cascade and linked its protease activity to cancer cell invasion.\",\n      \"evidence\": \"Pharmacological MEK inhibition (UO126) and protease antibody array in renal cell carcinoma cells\",\n      \"pmids\": [\"31438640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct transcription factor mediating ERK-to-CTSS transcription not identified\",\n        \"Relevance to non-cancer cell types not tested\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying TFEB as a direct transcriptional activator of CTSS downstream of mTORC1 inhibition, and Rab10-mTORC1 regulation of CTSS secretion via lysosomal exocytosis, defined a complete signaling-to-secretion axis for extracellular CTSS delivery.\",\n      \"evidence\": \"ChIP-qPCR, EMSA, luciferase reporter, IP-MS for Rab10-mTORC1, and in vivo atherosclerosis model in vascular smooth muscle cells\",\n      \"pmids\": [\"32640907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TFEB-CTSS axis operates in immune cells beyond vascular smooth muscle remains untested\",\n        \"Rab10-dependent exocytosis mechanism not reconstituted with purified components\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that dendritic cell-derived exosomal miR-203-3p directly targets CTSS to reduce foam cell formation introduced a post-transcriptional regulatory layer and linked CTSS to p38/MAPK-dependent lipid handling in macrophages.\",\n      \"evidence\": \"Luciferase target validation, gain/loss-of-function in macrophages, atherosclerosis mouse model\",\n      \"pmids\": [\"34077394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Endogenous miR-203-3p levels not manipulated in vivo specifically in DCs\",\n        \"Relative contribution of CTSS versus other miR-203-3p targets to foam cell phenotype unclear\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking CTSS enzymatic activity in macrophages and dendritic cells to enhanced MHC-dependent antigen presentation and anti-tumor CD8+ T cell responses established CTSS as a functional effector in antigen processing with therapeutic relevance.\",\n      \"evidence\": \"scRNA-seq of tumor-infiltrating immune cells, CTSS activity assays, syngeneic tumor models, human biopsy validation\",\n      \"pmids\": [\"35732347\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific MHC II-associated peptides generated by CTSS cleavage not identified\",\n        \"Whether CTSS-dependent antigen processing is tumor-antigen selective is unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that CTSS disrupts corneal epithelial barrier integrity by degrading tight junction proteins (ZO-1, occludin, claudin-1, E-cadherin) under TNF-α/hyperosmolar stress broadened the substrate repertoire of CTSS to include multiple junctional proteins.\",\n      \"evidence\": \"Primary human corneal epithelial cells, hyperosmolar model, confocal microscopy, cytokine treatments\",\n      \"pmids\": [\"36208723\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct cleavage of each junctional protein by CTSS not demonstrated with purified components\",\n        \"In vivo corneal barrier rescue by CTSS inhibition not shown\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that CTSS deficiency reduces stress-related thrombosis by attenuating vascular inflammation, oxidative stress, and endothelial apoptosis revealed a pro-thrombotic role for CTSS beyond matrix degradation.\",\n      \"evidence\": \"CTSS knockout mice, FeCl3-induced thrombosis model, gain/loss-of-function in HUVECs\",\n      \"pmids\": [\"37128920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific endothelial substrates cleaved by CTSS to promote apoptosis not identified\",\n        \"Contribution of extracellular versus intracellular CTSS activity not dissected\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying that CTSS drives airway neutrophilic inflammation via Akt-dependent E-cadherin shedding placed CTSS in the pathogenesis of mixed granulocytic asthma and defined E-cadherin as a functionally relevant substrate in airway epithelium.\",\n      \"evidence\": \"Intratracheal recombinant CTSS instillation, LY3000328 CTSS antagonism, Akt inhibitor rescue in murine asthma models\",\n      \"pmids\": [\"39719614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct cleavage site on E-cadherin not mapped\",\n        \"Whether Akt activation is a direct consequence of CTSS proteolysis or secondary to E-cadherin loss is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Elucidating that vNAR antibody fragments inhibit CTSS by blocking proCTSS maturation rather than active-site catalysis revealed that the proenzyme-to-mature conversion is a druggable regulatory step.\",\n      \"evidence\": \"Phage display, SPR binding, enzyme activity assays, intrabody expression in tumor invasion assay\",\n      \"pmids\": [\"38116078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis of vNAR binding to proCTSS not resolved\",\n        \"In vivo efficacy of maturation-blocking inhibitors not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that CTSS degrades BRCA1 protein to confer radioresistance in triple-negative breast cancer identified an unexpected nuclear/cytoplasmic tumor suppressor as a CTSS substrate with functional consequences for DNA damage response.\",\n      \"evidence\": \"Western blotting, CTSS enzyme assay, CTSS inhibitor TS-24, xenograft radiosensitization model\",\n      \"pmids\": [\"38613358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"BRCA1 cleavage site by CTSS not mapped\",\n        \"Subcellular compartment where CTSS encounters BRCA1 not defined\",\n        \"Generalizability beyond TNBC not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showing that CTSS knockdown in retinal pigment epithelial cells attenuates NF-κB-dependent inflammation, complement activation (C3a, C5a, MAC), and VEGF-A/Akt-driven angiogenesis under oxidative stress established CTSS as a multi-pathway amplifier of retinal pathology.\",\n      \"evidence\": \"siRNA knockdown in ARPE-19 cells, H2O2 stress model, tube formation assay, laser-induced choroidal neovascularization mouse model\",\n      \"pmids\": [\"38914301\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether CTSS directly cleaves complement components or acts indirectly via NF-κB is unresolved\",\n        \"RPE-specific CTSS knockout not performed\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying claudin-1 as a direct CTSS substrate in aged choroid plexus macrophages, whose cleavage impairs the blood-CSF barrier, and demonstrating that CTSS inhibition or CLDN1 overexpression restores barrier function and brain function, provided definitive in vivo substrate-to-phenotype evidence for CTSS in neuroinflammatory aging.\",\n      \"evidence\": \"In vivo CTSS inhibition, CLDN1 overexpression, biochemical cleavage assays, CSF barrier integrity readouts in aged mice\",\n      \"pmids\": [\"40015275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"CTSS cleavage site on claudin-1 not mapped at residue level\",\n        \"Contribution of other choroid plexus proteases not excluded\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Validating CTSS as a direct target of miR-214-3p and showing its role in high-glucose-induced extracellular matrix deposition in Müller cells via the LINC02099/miR-214-3p axis defined an additional post-transcriptional regulatory circuit relevant to diabetic retinopathy.\",\n      \"evidence\": \"Dual-luciferase reporter assay, siRNA/mimic experiments, in vivo diabetic mouse model\",\n      \"pmids\": [\"40965405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"ECM substrates directly cleaved or regulated by CTSS in Müller cells not identified\",\n        \"Whether CTSS acts extracellularly or intracellularly in ECM deposition context unknown\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrating that macrophage-derived amphiregulin upregulates CTSS via EGFR in Schwann cells to enhance myelin debris phagocytosis after nerve injury revealed a paracrine regulatory axis and a non-immune phagocytic function for CTSS.\",\n      \"evidence\": \"Areg conditional knockout mice, conditioned medium, CTSS rescue of phagocytic defects in Schwann cells\",\n      \"pmids\": [\"41708964\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How CTSS mechanistically promotes phagocytosis in Schwann cells is undefined\",\n        \"Whether CTSS cleaves myelin proteins directly or acts indirectly is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified structural and compartment-resolved model explaining how CTSS selects among its diverse substrates (claudin-1, E-cadherin, BRCA1, myelin debris) in different cell types and whether extracellular versus intracellular activity is the primary driver in each context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal structure of CTSS in complex with any validated substrate\",\n        \"Substrate specificity determinants beyond the active site not defined\",\n        \"Relative contributions of secreted versus lysosomal CTSS activity not systematically compared across tissues\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3, 5, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CLDN1\",\n      \"BRCA1\",\n      \"TFEB\",\n      \"RAB10\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Cathepsin S is a lysosomal cysteine endopeptidase with uniquely broad pH-range activity that serves as the essential protease for MHC class II antigen presentation by cleaving the invariant chain (Ii) to generate αβ-CLIP complexes competent for peptide loading [PMID:8612130, PMID:11884425]. Beyond its canonical immune function, CTSS proteolytically processes diverse extracellular and signaling substrates—including JAM-B (enabling blood–brain barrier transmigration and brain metastasis) [PMID:25086747], claudin-1 (disrupting the blood–CSF barrier during aging) [PMID:40015275], PAR2 (acting as a biased agonist coupling to Gαs/cAMP/TRPV4-dependent pain without β-arrestin recruitment) [PMID:25118282], IL-36γ (generating the bioactive psoriasis cytokine) [PMID:28289191], fibronectin (promoting adipogenesis) [PMID:16825321], SLPI (abolishing anti-elastase protection) [PMID:11435427], and BRCA1 (conferring radioresistance in triple-negative breast cancer) [PMID:38613358]. CTSS expression is transcriptionally controlled by TFEB downstream of mTORC1 inhibition and post-transcriptionally regulated by ADAR1-mediated A-to-I RNA editing that recruits HuR to stabilize CTSS mRNA [PMID:32640907, PMID:27595325]. In macrophages, CTSS promotes autophagic flux and autophagosome–lysosome fusion required for M2 polarization of tumor-associated macrophages, and its secretion is governed by Rab10/mTORC1-dependent lysosomal exocytosis [PMID:24580730, PMID:32640907].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Cloning of CTSS from human alveolar macrophages established it as a cysteine protease with elastinolytic activity retaining substantial function at neutral pH, distinguishing it from other cathepsins and suggesting extracellular roles.\",\n      \"evidence\": \"cDNA cloning, recombinant expression in COS cells, active-site labeling, elastin degradation at pH 5.5 and 7.0\",\n      \"pmids\": [\"1373132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure not yet available at this point\", \"In vivo substrates unknown\", \"Regulatory mechanisms uncharacterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of CTSS as the non-redundant protease required for the final step of invariant chain degradation in antigen-presenting cells resolved a long-standing question about how MHC class II molecules acquire antigenic peptides.\",\n      \"evidence\": \"Specific small-molecule inhibition in B lymphoblastoid cells causing Ii fragment accumulation; in vitro reconstitution showing only purified CTSS (not cathepsins B, H, or D) generates αβ-CLIP from αβIi trimers\",\n      \"pmids\": [\"8612130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cathepsin S contribution to antigen epitope generation versus Ii processing not yet separated\", \"Role in non-B cell APCs unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Subcellular fractionation placed CTSS predominantly in late endosomes and phagosomes of macrophages, while endogenous inhibitors (cystatin C, SCCA1) were characterized kinetically, defining the regulatory framework for CTSS activity in vivo.\",\n      \"evidence\": \"Organelle fractionation with enzyme activity readouts in J774 macrophages; kinetic inhibition assays with cystatin C mutants and SCCA1–CTSS complex formation\",\n      \"pmids\": [\"9545324\", \"7890620\", \"9548757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of SCCA1 inhibition unclear\", \"Mechanisms controlling CTSS secretion versus retention unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that CTSS degrades extracellular fibronectin to promote preadipocyte differentiation was among the first evidence that CTSS functions outside the endolysosomal compartment in a non-immune, tissue-remodeling context.\",\n      \"evidence\": \"Primary human preadipocyte cultures treated with recombinant CTSS or specific inhibitor; fibronectin immunostaining and adipocyte marker quantification\",\n      \"pmids\": [\"16825321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fibronectin cleavage site not mapped\", \"Contribution of other secreted cathepsins not fully excluded\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A burst of substrate discoveries—JAM-B cleavage enabling blood–brain barrier transmigration for breast cancer metastasis, biased agonist cleavage of PAR2 driving cAMP/TRPV4-dependent pain, and a role in autophagy-mediated M2 macrophage polarization—expanded CTSS biology far beyond invariant chain processing.\",\n      \"evidence\": \"JAM-B: xenograft metastasis models with combined tumor/macrophage CTSS depletion and pharmacological inhibition [PMID:25086747]; PAR2: cleavage site mapping at E56↓T57 with signaling dissection in HEK cells and PAR2/TRPV4-KO mice [PMID:25118282]; autophagy: CTSS-KO mice with mCherry-GFP-LC3 flux assay and TEM [PMID:24580730]\",\n      \"pmids\": [\"25086747\", \"25118282\", \"24580730\", \"24523067\", \"24875536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"JAM-B cleavage site not precisely mapped\", \"How CTSS enters the autophagy pathway mechanistically is unclear\", \"Whether PAR2 biased agonism by CTSS operates in all tissues unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that ADAR1-mediated A-to-I RNA editing in the CTSS 3′ UTR recruits HuR to stabilize CTSS mRNA revealed a novel post-transcriptional regulatory layer responsive to hypoxia and inflammatory cytokines, explaining CTSS upregulation in atherosclerosis.\",\n      \"evidence\": \"A-to-I editing sequencing, ADAR1 overexpression, HuR RNA immunoprecipitation, mRNA decay assays in endothelial cells, validation in patient atherosclerotic plaques\",\n      \"pmids\": [\"27595325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RNA editing regulation extends to non-endothelial cell types in vivo not established\", \"Identity of factors competing with HuR for unedited CTSS mRNA unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of CTSS as the major activator of pro-IL-36γ in keratinocytes, generating bioactive IL-36γ-Ser18 that induces psoriasiform changes, directly linked CTSS to psoriasis pathogenesis and a therapeutically actionable substrate.\",\n      \"evidence\": \"Mass spectrometry cleavage-site identification, siRNA confirmation, functional human skin-equivalent models, elevated CTSS in psoriasis patient samples\",\n      \"pmids\": [\"28289191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other cathepsins contribute to IL-36γ activation in vivo not excluded\", \"Clinical efficacy of CTSS inhibitors in psoriasis untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"TFEB was identified as a direct transcriptional activator of CTSS downstream of mTORC1 inhibition, while Rab10/mTORC1 signaling controls CTSS secretion via lysosomal exocytosis, establishing a dual transcriptional–secretory regulatory circuit.\",\n      \"evidence\": \"ChIP-qPCR, EMSA, and luciferase reporter confirming TFEB binding to CTSS promoter; IP-MS identifying Rab10; in vivo atherosclerosis model with CTSS inhibition\",\n      \"pmids\": [\"32640907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFEB regulation of CTSS operates in professional APCs unknown\", \"Rab10-dependent exocytosis mechanism not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"CTSS was shown to cleave claudin-1 (CLDN1) at the choroid plexus, establishing it as a mediator of age-related blood–CSF barrier breakdown; inhibiting CTSS or restoring CLDN1 rejuvenated barrier function and brain cognition in aged mice.\",\n      \"evidence\": \"Choroid plexus macrophage isolation, in vitro CLDN1 cleavage assay, aged mouse models with CTSS inhibition or CLDN1 overexpression, behavioral assessments\",\n      \"pmids\": [\"40015275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CLDN1 cleavage site not precisely defined\", \"Whether senolytic approaches can substitute for direct CTSS inhibition untested\", \"Human translational validation absent\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full structural basis for CTSS substrate selectivity across its many validated targets, whether CTSS-targeted therapeutics can achieve pathway-selective inhibition without compromising MHC class II-dependent immunity, and how CTSS activity is spatiotemporally coordinated between lysosomal, phagosomal, and extracellular compartments in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No comprehensive structural model explaining selectivity for diverse substrates\", \"No clinical trial data for CTSS inhibitors addressing therapeutic window\", \"In vivo imaging of CTSS compartment-specific activity lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 6, 8, 9, 10, 12, 16, 21, 23]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 6, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5, 17]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [8, 10, 16, 23, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 7, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6, 10, 12, 16, 21, 23]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 14, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 12, 14, 24]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PAR2\",\n      \"CLDN1\",\n      \"JAM-B\",\n      \"TFEB\",\n      \"ADAR1\",\n      \"HuR\",\n      \"BRCA1\",\n      \"RAB10\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}